Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

Inhibition of protein misfolding/aggregation using polyglutamine binding peptide QBP1 as a therapy for the polyglutamine diseases.

Popiel HA, Takeuchi T, Burke JR, Strittmatter WJ, Toda T, Wada K, Nagai Y.

Neurotherapeutics. 2013 Jul;10(3):440-6. doi: 10.1007/s13311-013-0184-7. Review.

2.

Bathing the brain.

Strittmatter WJ.

J Clin Invest. 2013 Mar;123(3):1013-5. doi: 10.1172/JCI68241. Epub 2013 Feb 22.

3.

Alzheimer’s disease: the new promise.

Strittmatter WJ.

J Clin Invest. 2012 Apr;122(4):1191. No abstract available.

4.

Medicine. Old drug, new hope for Alzheimer's disease.

Strittmatter WJ.

Science. 2012 Mar 23;335(6075):1447-8. doi: 10.1126/science.1220725. No abstract available.

PMID:
22442467
5.

The Aggregation Inhibitor Peptide QBP1 as a Therapeutic Molecule for the Polyglutamine Neurodegenerative Diseases.

Popiel HA, Burke JR, Strittmatter WJ, Oishi S, Fujii N, Takeuchi T, Toda T, Wada K, Nagai Y.

J Amino Acids. 2011;2011:265084. doi: 10.4061/2011/265084. Epub 2011 Jun 30.

6.

Genome-wide scan of copy number variation in late-onset Alzheimer's disease.

Heinzen EL, Need AC, Hayden KM, Chiba-Falek O, Roses AD, Strittmatter WJ, Burke JR, Hulette CM, Welsh-Bohmer KA, Goldstein DB.

J Alzheimers Dis. 2010;19(1):69-77. doi: 10.3233/JAD-2010-1212.

7.

A genome-wide investigation of SNPs and CNVs in schizophrenia.

Need AC, Ge D, Weale ME, Maia J, Feng S, Heinzen EL, Shianna KV, Yoon W, Kasperaviciūte D, Gennarelli M, Strittmatter WJ, Bonvicini C, Rossi G, Jayathilake K, Cola PA, McEvoy JP, Keefe RS, Fisher EM, St Jean PL, Giegling I, Hartmann AM, Möller HJ, Ruppert A, Fraser G, Crombie C, Middleton LT, St Clair D, Roses AD, Muglia P, Francks C, Rujescu D, Meltzer HY, Goldstein DB.

PLoS Genet. 2009 Feb;5(2):e1000373. doi: 10.1371/journal.pgen.1000373. Epub 2009 Feb 6. Erratum in: PLoS Genet. 2009 Mar;5(3). doi: 10.1371/annotation/e0196ebb-de40-453f-8f8c-791b126618da.

8.

Identification of chemical inhibitors to human tissue transglutaminase by screening existing drug libraries.

Lai TS, Liu Y, Tucker T, Daniel KR, Sane DC, Toone E, Burke JR, Strittmatter WJ, Greenberg CS.

Chem Biol. 2008 Sep 22;15(9):969-78. doi: 10.1016/j.chembiol.2008.07.015.

9.

Apolipoprotein E genotype as a determinant of survival in chronic lymphocytic leukemia.

Weinberg JB, Volkheimer AD, Mihovilovic M, Jiang N, Chen Y, Bond K, Moore JO, Gockerman JP, Diehl LF, de Castro CM, Rizzieri DA, Levesque MC, Dekroon R, Strittmatter WJ.

Leukemia. 2008 Dec;22(12):2184-92. doi: 10.1038/leu.2008.241. Epub 2008 Sep 11.

PMID:
18784741
10.

Optimization of a polyglutamine aggregation inhibitor peptide (QBP1) using a thioflavin T fluorescence assay.

Hamuro L, Zhang G, Tucker TJ, Self C, Strittmatter WJ, Burke JR.

Assay Drug Dev Technol. 2007 Oct;5(5):629-36.

PMID:
17939755
11.

High-fat/high-cholesterol diet promotes a S1P receptor-mediated antiapoptotic activity for VLDL.

Mihovilovic M, Robinette JB, DeKroon RM, Sullivan PM, Strittmatter WJ.

J Lipid Res. 2007 Apr;48(4):806-15. Epub 2007 Jan 30.

12.

Mortalin is regulated by APOE in hippocampus of AD patients and by human APOE in TR mice.

Osorio C, Sullivan PM, He DN, Mace BE, Ervin JF, Strittmatter WJ, Alzate O.

Neurobiol Aging. 2007 Dec;28(12):1853-62. Epub 2006 Oct 16.

PMID:
17050040
13.

Phage display screening for peptides that inhibit polyglutamine aggregation.

Kenan DJ, Strittmatter WJ, Burke JR.

Methods Enzymol. 2006;413:253-73.

PMID:
17046401
14.

APOE4-VLDL inhibits the HDL-activated phosphatidylinositol 3-kinase/Akt Pathway via the phosphoinositol phosphatase SHIP2.

DeKroon R, Robinette JB, Hjelmeland AB, Wiggins E, Blackwell M, Mihovilovic M, Fujii M, York J, Hart J, Kontos C, Rich J, Strittmatter WJ.

Circ Res. 2006 Oct 13;99(8):829-36. Epub 2006 Sep 14.

PMID:
16973905
15.

Polyglutamine expansion inhibits respiration by increasing reactive oxygen species in isolated mitochondria.

Puranam KL, Wu G, Strittmatter WJ, Burke JR.

Biochem Biophys Res Commun. 2006 Mar 10;341(2):607-13. Epub 2006 Jan 13.

PMID:
16427603
16.

APOE2 allele increased in tardive dyskinesia.

Halford J, Mazeika G, Slifer S, Speer M, Saunders AM, Strittmatter WJ, Morgenlander JC.

Mov Disord. 2006 Apr;21(4):540-2.

PMID:
16261623
17.

Apolipoprotein E and brain injury: implications for children.

Blackman JA, Worley G, Strittmatter WJ.

Dev Med Child Neurol. 2005 Jan;47(1):64-70. Review. No abstract available.

PMID:
15686292
18.

Disrupted spermine homeostasis: a novel mechanism in polyglutamine-mediated aggregation and cell death.

Colton CA, Xu Q, Burke JR, Bae SY, Wakefield JK, Nair A, Strittmatter WJ, Vitek MP.

J Neurosci. 2004 Aug 11;24(32):7118-27.

19.

Disruption of the toxic conformation of the expanded polyglutamine stretch leads to suppression of aggregate formation and cytotoxicity.

Popiel HA, Nagai Y, Onodera O, Inui T, Fujikake N, Urade Y, Strittmatter WJ, Burke JR, Ichikawa A, Toda T.

Biochem Biophys Res Commun. 2004 May 14;317(4):1200-6.

PMID:
15094397
20.

Effect of tissue transglutaminase on the solubility of proteins containing expanded polyglutamine repeats.

Lai TS, Tucker T, Burke JR, Strittmatter WJ, Greenberg CS.

J Neurochem. 2004 Mar;88(5):1253-60.

21.

APOE genotype-specific differences in human and mouse macrophage nitric oxide production.

Colton CA, Needham LK, Brown C, Cook D, Rasheed K, Burke JR, Strittmatter WJ, Schmechel DE, Vitek MP.

J Neuroimmunol. 2004 Feb;147(1-2):62-7.

PMID:
14741429
22.

Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila.

Nagai Y, Fujikake N, Ohno K, Higashiyama H, Popiel HA, Rahadian J, Yamaguchi M, Strittmatter WJ, Burke JR, Toda T.

Hum Mol Genet. 2003 Jun 1;12(11):1253-9.

PMID:
12761040
23.

ApoE genotype-specific inhibition of apoptosis.

DeKroon RM, Mihovilovic M, Goodger ZV, Robinette JB, Sullivan PM, Saunders AM, Strittmatter WJ.

J Lipid Res. 2003 Aug;44(8):1566-73. Epub 2003 May 16.

24.

In vitro effects of polyglutamine tracts on Ca2+-dependent depolarization of rat and human mitochondria: relevance to Huntington's disease.

Panov AV, Burke JR, Strittmatter WJ, Greenamyre JT.

Arch Biochem Biophys. 2003 Feb 1;410(1):1-6.

PMID:
12559971
25.

Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines.

Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, Greenamyre JT.

Nat Neurosci. 2002 Aug;5(8):731-6.

PMID:
12089530
26.

Expanded polyglutamine stretches form an 'aggresome'.

Shimohata T, Sato A, Burke JR, Strittmatter WJ, Tsuji S, Onodera O.

Neurosci Lett. 2002 May 3;323(3):215-8.

PMID:
11959423
27.

Molecular biology of apolipoprotein E.

Strittmatter WJ, Bova Hill C.

Curr Opin Lipidol. 2002 Apr;13(2):119-23. Review.

PMID:
11891413
28.

Amino acid sequence requirements of peptides that inhibit polyglutamine-protein aggregation and cell death.

Ren H, Nagai Y, Tucker T, Strittmatter WJ, Burke JR.

Biochem Biophys Res Commun. 2001 Nov 2;288(3):703-10.

PMID:
11676500
29.

Apolipoprotein E and Alzheimer's disease: signal transduction mechanisms.

Strittmatter WJ.

Biochem Soc Symp. 2001;(67):101-9. Review.

PMID:
11447826
30.

Impairment of the blood-nerve and blood-brain barriers in apolipoprotein e knockout mice.

Fullerton SM, Shirman GA, Strittmatter WJ, Matthew WD.

Exp Neurol. 2001 May;169(1):13-22.

PMID:
11312553
31.

Apolipoprotein E and Alzheimer's disease.

Strittmatter WJ.

Ann N Y Acad Sci. 2000;924:91-2. Review.

PMID:
11193808
32.

Apolipoprotein E and neuromuscular disease: a critical review of the literature.

Bedlack RS, Strittmatter WJ, Morgenlander JC.

Arch Neurol. 2000 Nov;57(11):1561-5. Review.

PMID:
11074787
33.

Preliminary report on the association of apolipoprotein E polymorphisms, with postoperative peak serum creatinine concentrations in cardiac surgical patients.

Chew ST, Newman MF, White WD, Conlon PJ, Saunders AM, Strittmatter WJ, Landolfo K, Grocott HP, Stafford-Smith M.

Anesthesiology. 2000 Aug;93(2):325-31.

PMID:
10910477
34.

The role of apolipoprotein E in Alzheimer's disease: pharmacogenomic target selection.

Saunders AM, Trowers MK, Shimkets RA, Blakemore S, Crowther DJ, Mansfield TA, Wallace DM, Strittmatter WJ, Roses AD.

Biochim Biophys Acta. 2000 Jul 26;1502(1):85-94. Review.

35.

Inhibition of polyglutamine protein aggregation and cell death by novel peptides identified by phage display screening.

Nagai Y, Tucker T, Ren H, Kenan DJ, Henderson BS, Keene JD, Strittmatter WJ, Burke JR.

J Biol Chem. 2000 Apr 7;275(14):10437-42.

36.

Polyglutamine domain proteins with expanded repeats bind neurofilament, altering the neurofilament network.

Nagai Y, Onodera O, Strittmatter WJ, Burke JR.

Ann N Y Acad Sci. 1999;893:192-202.

PMID:
10672238
37.

Expanded polyglutamine domain proteins bind neurofilament and alter the neurofilament network.

Nagai Y, Onodera O, Chun J, Strittmatter WJ, Burke JR.

Exp Neurol. 1999 Feb;155(2):195-203.

PMID:
10072295
38.

Pathogenesis of inclusion bodies in (CAG)n/Qn-expansion diseases with special reference to the role of tissue transglutaminase and to selective vulnerability.

Cooper AJ, Sheu KF, Burke JR, Strittmatter WJ, Gentile V, Peluso G, Blass JP.

J Neurochem. 1999 Mar;72(3):889-99. Review.

39.
40.

Glyceraldehyde 3-phosphate dehydrogenase abnormality in metabolically stressed Huntington disease fibroblasts.

Cooper AJ, Sheu KF, Burke JR, Strittmatter WJ, Blass JP.

Dev Neurosci. 1998;20(4-5):462-8.

PMID:
9778585
41.

Peripheral sensory nerve defects in apolipoprotein E knockout mice.

Fullerton SM, Strittmatter WJ, Matthew WD.

Exp Neurol. 1998 Sep;153(1):156-63.

PMID:
9743578
42.

Human apolipoprotein E accelerates microtubule polymerization in vitro.

Scott BL, Welch K, deSerrano V, Moss NC, Roses AD, Strittmatter WJ.

Neurosci Lett. 1998 Apr 3;245(2):105-8.

PMID:
9605496
43.

Novel large apolipoprotein E-containing lipoproteins of density 1.006-1.060 g/ml in human cerebrospinal fluid.

Guyton JR, Miller SE, Martin ME, Khan WA, Roses AD, Strittmatter WJ.

J Neurochem. 1998 Mar;70(3):1235-40.

45.

Transglutaminase-catalyzed inactivation of glyceraldehyde 3-phosphate dehydrogenase and alpha-ketoglutarate dehydrogenase complex by polyglutamine domains of pathological length.

Cooper AJ, Sheu KR, Burke JR, Onodera O, Strittmatter WJ, Roses AD, Blass JP.

Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12604-9.

46.

Preliminary report of a genetic basis for cognitive decline after cardiac operations. The Neurologic Outcome Research Group of the Duke Heart Center.

Tardiff BE, Newman MF, Saunders AM, Strittmatter WJ, Blumenthal JA, White WD, Croughwell ND, Davis RD Jr, Roses AD, Reves JG.

Ann Thorac Surg. 1997 Sep;64(3):715-20.

PMID:
9307463
47.

Oligomerization of expanded-polyglutamine domain fluorescent fusion proteins in cultured mammalian cells.

Onodera O, Burke JR, Miller SE, Hester S, Tsuji S, Roses AD, Strittmatter WJ.

Biochem Biophys Res Commun. 1997 Sep 18;238(2):599-605.

PMID:
9299559
48.

Apolipoprotein E binds to and potentiates the biological activity of ciliary neurotrophic factor.

Gutman CR, Strittmatter WJ, Weisgraber KH, Matthew WD.

J Neurosci. 1997 Aug 15;17(16):6114-21.

49.

Polyglutamine domains are substrates of tissue transglutaminase: does transglutaminase play a role in expanded CAG/poly-Q neurodegenerative diseases?

Cooper AJ, Sheu KF, Burke JR, Onodera O, Strittmatter WJ, Roses AD, Blass JP.

J Neurochem. 1997 Jul;69(1):431-4.

50.

Toxicity of expanded polyglutamine-domain proteins in Escherichia coli.

Onodera O, Roses AD, Tsuji S, Vance JM, Strittmatter WJ, Burke JR.

FEBS Lett. 1996 Dec 9;399(1-2):135-9.

Supplemental Content

Loading ...
Support Center